Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.
about
The hypocretin/orexin systemChronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapseElevated midpregnancy corticotropin-releasing hormone is associated with prenatal, but not postpartum, maternal depressionThe dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid systemMifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implicationsCRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndromePsychological stress and fibromyalgia: a review of the evidence suggesting a neuroendocrine linkPharmacological treatment of anxiety disorders: current treatments and future directionsBehavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.Current investigational drugs for major depressionEmerging targets for antidepressant therapiesNew approaches to antidepressant drug discovery: beyond monoaminesDecreased amygdala CRF-binding protein mRNA in post-mortem tissue from male but not female bipolar and schizophrenic subjectsNew developments in the pharmacotherapy of cocaine abuseRole of corticotropin-releasing factor (CRF) receptor-1 on the catecholaminergic response to morphine withdrawal in the nucleus accumbens (NAc)Pain-related anxiety-like behavior requires CRF1 receptors in the amygdalaCRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behaviorNovel targets for antidepressant therapiesBipolar disorder: candidate drug targets.Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitusDon't stress about CRF: assessing the translational failures of CRF1antagonists.Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment.Major depression is not associated with blunting of aversive responses; evidence for enhanced anxious anticipation.The CRF system, stress, depression and anxiety-insights from human genetic studies.Behavioral Studies and Genetic Alterations in Corticotropin-Releasing Hormone (CRH) Neurocircuitry: Insights into Human Psychiatric Disorders.Persistent anxiolytic affects after chronic administration of the CRF₁ receptor antagonist R121919 in rats.Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention.Angst and the amygdalaGlucocorticoid receptor dysfunction: consequences for the pathophysiology and treatment of mood disorders.Pharmacotherapy of PTSD: premises, principles, and prioritiesDifferential blockade of CRF-evoked behaviors by depletion of norepinephrine and serotonin in rats.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsCorticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent ratsThe CRF system mediates increased passive stress-coping behavior following the loss of a bonded partner in a monogamous rodent.Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleepRole of corticotropin releasing factor in anxiety disorders: a translational research perspectiveCorticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.Corticotropin-releasing factor receptors and stress-related alterations of gut motor function.Loss of hypothalamic corticotropin-releasing hormone markedly reduces anxiety behaviors in mice.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.
P2860
Q24537243-20371ABD-A066-4AB4-8790-C03BB2D1C7B3Q24633835-1D6304CD-D9E7-48F8-996C-E20EA620DD3BQ24654669-4F1D6C15-EC9D-4EF6-84DA-CAA3C666CEA4Q24655164-9372D92E-E11E-4809-90D2-B87EE38ABE7AQ24656111-D85A259E-905F-4C86-98A0-2C19C7D98380Q24671910-2E472227-3DEA-465C-9445-7DE3BFBBD4AEQ24801007-1F7959C9-5630-4C78-BEB0-6B3EDCDC6DC0Q26851461-97D2004A-AA8F-42DC-8D87-57F9E23190F1Q27014879-A46824A2-9CE0-4790-AA01-FF4EE5BA620EQ28244223-BA35F705-6DB8-4514-9215-91AE32DEB528Q28247614-4BBE87B2-59C4-4D10-94B1-6CB350D512E8Q28293089-C2B6075D-884E-4E68-AD5F-EA0199672FCAQ28297733-B6EE0AA8-C67A-41CC-9F4A-82FF0EB4EC31Q28302782-9E79711F-6819-4F6F-833F-C1D3FD5914ACQ28484325-31CD0C50-795C-4F8D-9D14-8AA975759654Q28569513-F8706D9F-FA93-419D-9F04-E2995FDA289BQ28580222-0654293A-2A44-4487-BC02-8CD82CACD7FEQ28648254-DDF3815A-7825-4BAC-8C11-5F6BC1B5F141Q28751133-C4D63599-DBD2-4C26-90C0-E0689F8259E2Q28917159-77112292-73BD-4950-8BB4-9D5DDE241FC1Q30399543-BCC4415B-8BFD-4F5D-901C-488118ED98C0Q30442231-EF046AFA-947E-4ED9-8DA9-74FCC8DB269FQ30450782-8C5B3815-7A6F-494A-958D-9C938904D33FQ30454302-FE57AF5C-5D96-484B-93F4-321980E38090Q30462467-25A412AC-7DEA-4DDE-A3BF-7817C0B30887Q30467178-F9EB43C2-BBA5-48E0-857D-E88615291B92Q30468942-19CDC485-3DDA-41CB-B43B-2D6CF8AF496FQ30473413-63CCF606-8B65-4313-8AD8-61FFCBA3C5B4Q30477689-A645ED65-5A3D-4107-ACFC-0E9ED93C6D1AQ30479154-10B3E356-5E6E-4E7A-8798-8ABC259E3AEDQ30486659-50C01539-A0DB-4B3A-9D89-C0D652572CCCQ30486707-1C1C2579-F42A-4B8A-AF48-D4F82D89C9BAQ30486793-18521800-3702-4D5E-99BB-56D8646C2BE3Q30487068-495F4BC3-A0E4-4B57-A86F-76F81D3356BDQ30493526-F2C1F38D-7595-4681-AAC2-D6C28748E232Q30498732-36EA1B6E-2D87-4E19-91BB-A66A53CFDA9DQ30502566-815092AD-A5BB-478C-BE08-70BB97DE2DE9Q30542062-16B55BA6-E656-486D-87B0-4C1680634525Q30840778-0A9ADE3A-E140-4B9F-8C01-AC8497B07DBCQ31121208-8E05F778-BF3A-4FE4-B11A-0FB9D40DA835
P2860
Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Effects of the high-affinity c ...... the first 20 patients treated.
@en
Effects of the high-affinity c ...... the first 20 patients treated.
@nl
type
label
Effects of the high-affinity c ...... the first 20 patients treated.
@en
Effects of the high-affinity c ...... the first 20 patients treated.
@nl
prefLabel
Effects of the high-affinity c ...... the first 20 patients treated.
@en
Effects of the high-affinity c ...... the first 20 patients treated.
@nl
P2093
P1476
Effects of the high-affinity c ...... the first 20 patients treated.
@en
P2093
Holsboer F
P304
P356
10.1016/S0022-3956(00)00016-9
P577
2000-05-01T00:00:00Z